Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab reinduction in IBD after drug holiday
NCT02771457Phase 3Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jul 2016
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), sponsored by NYU Langone Health. Primary endpoint: Failure Rate at 1 year. Planned start Jul 2016; status: withdrawn.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02771457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771457.